1826 ET - As Hims & Hers Health continues to revamp its offerings to focus on personalization, it's turning its attention toward its sexual health specialty, where most subscribers have historically favored "on-demand" solutions, the company said in a letter to shareholders. Such treatments limit personalized benefits, so Hims has looked to focus on users who would benefit from a more precise daily solution. The transition has slowed customer acquisition within the segment, but subscriber and revenue growth outside of the company's popular GLP-1 weight loss drugs were still nearly 30% in 1Q. "Our approach is to align our investments toward long-term value creation, even if that results in temporary near-term headwinds for the business," the company said. (kelly.cloonan@wsj.com)
(END) Dow Jones Newswires
May 05, 2025 18:27 ET (22:27 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。